|Mr. Mark M. Sieczkarek||Chairman, CEO & Pres||453.5k||N/A||1955|
|Mr. Justin M. Hall||Sr. VP & Gen. Counsel||253.5k||N/A||1978|
|Mr. John J. McGovern||CFO, Treasurer & Principal Accounting Officer||N/A||N/A||N/A|
|Dr. David W. Stroman Ph.D.||Sr. VP of Ophthalmic Product Devel. and Chair of Ophthalmology Advisory Board||N/A||N/A||1945|
|Mr. Lewis J. Stuart BA, MBA||Chief Commercial Officer||N/A||N/A||1959|
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
NovaBay Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.